European Union advises adding condition to AstraZeneca vaccine label

European Union advises adding condition to AstraZeneca vaccine label



The European Medicines Agency says it’s recommending that people who have had a rare blood vessel syndrome not be immunised with AstraZeneca’s COVID-19 vaccine.


In a statement on Friday, the EU drug regulator said it reviewed cases of six people who had capillary leak syndrome after they had received a shot of the AstraZeneca vaccine.





The vaccine has previously been linked to rare blood clots, but health officials say its benefits still outweigh the small risks.


EMA experts also concluded that the capillary leak condition should be added to the product information as a new side effect of the vaccine.


The agency said it is continuing its review of heart inflammation in a small number of people who developed conditions after getting immunized with the vaccines made by Pfizer-BioNTech or Moderna Inc.


The EMA said it is studying cases of myocarditis, inflammation of the heart, and pericarditis, inflammation of the membrane surrounding the heart. Symptoms include shortness of breath and chest pain; the problems are usually temporary.


Further analysis is needed to determine whether there is a causal link with the vaccines, the EU agency said.


The EMA said it expects to finalize its review of such cases next month.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *